Groowe Groowe / Newsroom / INCY
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

INCY News

Incyte Genomics Inc

Incyte anuncia una opinión positiva de Zynyz ® (retifanlimab) del CMUH para tratamiento de primera línea del carcinoma de células escamosas del canal anal avanzado

businesswire.com
INCY

Incyte kondigt positief CHMP-advies aan voor Zynyz ® (retifanlimab) voor de eerstelijnsbehandeling van gevorderd plaveiselcelcarcinoom van de anus (SCAC)

businesswire.com
INCY

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

businesswire.com
INCY

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

globenewswire.com
INCY

Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR

globenewswire.com
REGN LLY AMGN SNY ABBV INCY GSK PFG DERM

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

businesswire.com
INCY

Vitiligo Treatment Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast to 2031

globenewswire.com
INCY

Molecular Switch Targeting Therapies Market Research Report 2026: Opportunities in Targeted Drug Delivery Systems and Therapies in Oncology, Autoimmune, Inflammatory, and Neurological Disorders

globenewswire.com
MRK BMY AZN PFE NVS LLY GILD JNJ REGN ABBV NVO SNY VRTX AMGN BIIB INCY EXEL SRPT CRSP EDIT NTLA ALNY MRNA BNTX COHR IMUX INSM CYTK KODK LULU NVDA GOOG MSFT IBM AMAT ILMN ALKS ACAD MNKD TEVA BHC XBI IBB XLF XLK XLV JAZZ ACGL

House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight USA - English USA - English

prnewswire.com
ALKS STG GSK SNY TEVA AZN INCY REGN PFE BMY LLY AMGN ABBV GILD BIIB CSL VRTX BHC NVS MRK LEO ALLT CNTB INM

Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight

prnewswire.com
TAK JNJ CANF AMGN ABBV NVS BMY AZN BHC LLY UCB LEO REGN XBI IBB JAZZ MRK SNY GILD INCY PFE LULU PRTH DRH BIIB TEVA ARCT HRMY CRSP NTLA EDIT SNOW DDOG CRM GOOG MSFT AAPL AMZN TSLA NVDA META NFLX DIS CMCSA VZ T KO PEP MCD SBUX HD EXAS ILMN BNTX MRNA XOM CVX BA CAT GE IBM INTC CSCO ADBE QCOM AMAT MU ORCL ACN COST WMT TGT LOW HON GD LMT RTX BAX